|
Market Cap (5-Jun) $18,417,672 (949th) |
Close (30-Jun) $0.005 |
Volume (30-Jun) 14,697,042 |
Shortsold (2-Apr) 218 (0.00%) (630th) |
|
52w High $9.00 |
52w Low $0.300 |
P/E 14.90 |
EPS -3.21 |
MXC released this announcement to the ASX on 16 June 2022, 15:30. The announcement is marked as price sensitive, and is 4 page(s) in length and 1.14MB in size.
You can view all announcements from MXC and see how they appear on a price chart on the announcements page.
At the date of this announcement, MXC was 0.021% short sold according to ASIC data. It was ranked the 611th most shorted stock on the ASX. It remains ranked 630th as of the latest reported data (02 April 2024).
| Other Recent Announcements from MXC | |
|---|---|
| Details of Company Address | 30 June 2023, 17:34 |
| Company Update | 30 June 2023, 17:24 |
| Results of Meeting | 29 June 2023, 18:43 |
| Glioblastoma pre-clinical trial results | 16 June 2022, 15:30 |
| Cognicann Clinical Trial Results | 6 June 2022, 15:23 |
| Response to ASX Aware Query | 18 May 2022, 9:07 |
| s708A(5)(e) Cleansing Notice | 13 May 2022, 19:03 |
You must be logged in to post a reply.
MGC Pharmaceuticals 